Jump to any asset
849 assets, updated daily
As of September 27, 2026, QuidelOrtho Corporation (QDEL) trades at $10.94. CleaRank Financial AI rates it Sell with a fair value of $10.56, 3.5% below the current price. Wall Street's consensus target is $12.00 across 3 analysts. RSI at 24 is in oversold territory, and the price is below its 50-day average of $14.21.
QuidelOrtho Corporation (QDEL)
QuidelOrtho Corporation NASDAQ
$10.94
0.2500 (2.34%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
21 / 100
QuidelOrtho Corporation (QDEL) is currently trading at $10.94, significantly below its 50-day and 200-day moving averages ($14.21 and $18.43), indicating a bearish technical trend. The company's financial health is challenged by negative EPS of -15.43 and a profit margin of -39.20%, contributing to a low consensus score of 21 and a 'Sell' rating. Despite these headwinds, insiders are net sellers, investing $1.2 million against $112,000 in sales, signaling moderate confidence in the company's future prospects. Recent earnings reports show mixed results, with a significant EPS beat in the quarter to June 2026 (0.13 actual vs. -0.05 estimate), but this was accompanied by a substantial price drop of -24.69%. Revenue is also trending downwards, with current quarter estimates showing a -10.00% year-over-year decline. The company's valuation metrics are difficult to assess due to negative EPS, but its price-to-sales ratio of 0.28 is well below the sector median of 3.70, suggesting it may be undervalued on a sales basis.
QDEL Price Analysis
Market Metrics
Open
$10.69
Day Range
$10.42 to $10.95
Prev Close
$10.69
Volume
1.38M
52-Week Range
$9.92 to $35.58
Market Cap
$750.22M
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, QDEL trades at 0.2805x, far below the sector average of 3.70x.
QDEL Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 1 quarters, QDEL beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
QDEL Analysis
Company's Health
2/5
12-Month Analyst Target
+9.69% Upside
Median of 3 analysts (12-month)
$12.00
AI Technical Analysis
Volume behavior for QuidelOrtho Corporation has been below average, with the latest volume at 1.38 million compared to a 1.81 million average, a decrease of 23.9%. The stock is trading below its 50-day SMA ($14.21) and 200-day SMA ($18.43), and its 20-day EMA ($11.93), reinforcing a bearish trend. The Relative Strength Index (RSI) is at 23.83, indicating an oversold condition, which could suggest a potential short-term bounce, but the MACD at -1.08 points to bearish momentum. Key support levels are not clearly defined given the downward trend, but the current price of $10.94 is approaching the lower end of its recent trading range. Resistance is expected around the 20-day EMA at $11.93 and then the 50-day SMA at $14.21. The oversold RSI suggests a possibility of a reversal, but the persistent trading below key moving averages and below-average volume do not yet support a bullish outlook.
ProTips
- Insider buying of $1.2 million suggests some confidence, but monitor upcoming earnings for signs of operational improvement to validate this signal.
- The stock is oversold (RSI 23.83), which may precede a short-term bounce, but the trend remains bearish as it trades below key moving averages.
- Given the negative EPS and high debt-to-equity ratio, investors should exercise caution and consider a tight stop-loss strategy if entering a long position.
Key Catalysts
Bullish
Insider Net Buying Activity
Insiders have purchased $1.2 million worth of stock against $112,000 in sales, indicating moderate confidence in the company's future prospects.
Source: Insider Trading DataBullish
Significant EPS Beat in Recent Quarter
The company reported an EPS of $0.13 for the quarter to June 2026, significantly exceeding the estimated -0.05, a 360% surprise.
Source: Earnings ReportBearish
Negative Profitability and Declining Revenue
The company continues to report negative EPS (-15.43) and profit margins (-39.20%), with forward revenue estimates indicating a continued contraction.
Source: Financial AnalysisBearish
Bearish Technical Trend
QuidelOrtho Corporation is trading below its 50-day and 200-day moving averages ($14.21 and $18.43), signaling a sustained bearish trend.
Source: Technical AnalysisMarket Outlook
The base case scenario for QuidelOrtho Corporation anticipates continued price pressure in the near term, with potential downside towards its long-range projection of $2.93 by 2030, given the current bearish technicals and negative financial trajectory. The median analyst target price of $12.00 suggests limited upside from the current $10.94, reflecting Wall Street's cautious 'Hold' rating. Upside potential could emerge if the company demonstrates a clear path to profitability and revenue growth, potentially driven by new product cycles or market share gains. Conversely, failure to improve earnings, coupled with its high debt load, could accelerate a decline towards the lower end of the long-range projection. The recent insider buying, while positive, needs to be validated by improving operational performance to shift the overall outlook.
Key Statistics
| Market Cap | 750.22M |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -15.43 |
| Dividend Yield | 0.00% |
| 52 Week High | 35.58 |
| 52 Week Low | 9.92 |
QuidelOrtho Corporation's valuation is currently obscured by negative earnings, with a reported EPS of -15.43 and a negative profit margin of -39.20%. This makes traditional P/E ratio analysis impossible, but the price-to-sales ratio stands at a low 0.28, significantly below the Healthcare sector median of 3.70. The company's debt-to-equity ratio is 1.73, which is higher than the sector average of 1.73, indicating a substantial reliance on debt financing. Despite the negative profitability, the company's revenue growth has been slightly positive at 2.8%, though forward estimates suggest a decline. Return on equity is significantly negative at -45.91%. The low price-to-sales ratio, combined with insider buying activity, might suggest a potential value act for investors willing to overlook current profitability challenges and focus on a turnaround, but the high debt levels and negative margins present significant risks.
Earnings & Growth Analysis
QuidelOrtho Corporation's recent earnings performance has been mixed, with a notable EPS beat in the quarter ending June 2026, reporting $0.13 actual versus an estimated -0.05, a 360% surprise. However, this positive surprise was met with a significant price decline of -24.69%. Prior quarters also show volatility, including a substantial EPS miss in the quarter to March 2026 (-0.04 actual vs. 0.36 estimate). Forward revenue estimates indicate a continued contraction, with the current quarter projected to see a -10.00% year-over-year decline.
Key Risks
The primary risk for QuidelOrtho Corporation is its persistent negative profitability, evidenced by a -39.20% net profit margin and a -15.43 EPS, which raises concerns about long-term viability. Additionally, the company is trading significantly below its key moving averages, with the RSI in oversold territory, suggesting potential for further downside pressure. The high debt-to-equity ratio of 1.73 also presents a financial risk, especially if revenue continues to decline and interest expenses increase.
Technical Indicators
| RSI (14) | 23.83 |
|---|---|
| MACD | -1.08 |
| SMA 50 | 14.21 |
| SMA 200 | 18.43 |
RSI
Oversold
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $14.21, 200-day: $18.43), price is trading below the 50-day SMA, RSI at 23.8 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.36
Weak correlation
Nasdaq 100 (QQQ)
+0.32
Weak correlation
Bitcoin (BTC)
+0.08
Weak correlation
Gold (XAU)
+0.06
Weak correlation
Check Custom Correlation
How does any other asset move with QDEL? One year of daily closes, Pearson correlation.
Try
QDEL Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Short entry pick an entry style
Conservative
$11.16
2% above current price
Lower risk, wait for rally
Aggressive
$10.94
Short at current price
Higher risk, chasing the move
Risk Management
STOP LOSS
$12.10
MAX LOSS
-8.4%
Volatility-Adjusted Stop Loss
Calculated based on RSI (23.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$10.60
-5% (Conservative)
-3.1% (Aggressive)
TARGET 2
$10.04
-10% (Conservative)
-8.2% (Aggressive)
TARGET 3
$9.485
-15% (Conservative)
-13.3% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
QDEL is classified as a high-volatility asset (Daily Vol: 3.64%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in QDEL in September 2016 would be worth about $4,948 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in QDEL today could grow to about $9,148 by 2036 in the base case, with a bull case near $69,400 and a bear case around $1,206. Projections are statistical simulations, not guarantees.
QDEL Stock Price Prediction: 2030
CleaRank's simulation projects a price near $10.56 for QDEL by 2030 in the base case, from $10.94 today (1.0x over 4 years). The downside path ends near $2.93. These are outcomes of a Monte Carlo simulation run on QDEL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $5.71 | $10.84 | $20.58 |
| 2028 | $4.34 | $10.75 | $26.60 |
| 2029 | $3.51 | $10.65 | $32.32 |
| 2030 | $2.93 | $10.56 | $38.03 |
| 2031 | $2.50 | $10.46 | $43.85 |
| 2032 | $2.16 | $10.37 | $49.83 |
| 2033 | $1.89 | $10.28 | $56.01 |
| 2034 | $1.66 | $10.19 | $62.40 |
| 2035 | $1.48 | $10.10 | $69.04 |
| 2036 | $1.32 | $10.01 | $75.92 |
Method: 10,000 simulated price paths using QDEL's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
QDEL Insider Trading Analysis
Bought
$1.2M
8 Transactions
Sold
$112.0K
1 Transactions
Insiders
18
Active Traders
Avg Transaction
$151.1K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 21, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 8.3M | $291.7M |
| Jul 25, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 621.5K | $24.1M |
| Aug 2, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 404.4K | $16.9M |
| Jul 31, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 315.5K | $12.4M |
| May 22, 2020 | KROLL WERNER
Officer
|
Sell | 68.2K | $11.9M |
| Jul 29, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 262.0K | $10.2M |
| Jul 23, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 234.8K | $8.4M |
| Aug 6, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 205.1K | $8.3M |
| Jun 17, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 227.6K | $8.2M |
| Jun 13, 2024 | CARLYLE GROUP, INC.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 208.5K | $8.0M |
Page 1 of 1
Frequently Asked Questions
What is QuidelOrtho Corporation's current stock price and rating?
QuidelOrtho Corporation (QDEL) is currently trading at $10.94 per share. The consensus rating among analysts is 'Sell', with a consensus score of 21 out of 100.
Is QuidelOrtho Corporation stock a buy right now?
Based on current data, QuidelOrtho Corporation is rated a 'Sell' with a consensus score of 21. The stock is trading below key moving averages and faces challenges with negative earnings and declining revenue, despite some recent insider buying.
What are QuidelOrtho Corporation's key technical indicators?
QuidelOrtho Corporation's technical indicators show the stock is oversold, with an RSI at 23.8. However, it is trading below its 50-day and 200-day moving averages ($14.21 and $18.43), indicating a bearish trend.
What is the outlook for QuidelOrtho Corporation's revenue?
Forward revenue estimates for QuidelOrtho Corporation suggest a continued contraction, with the current quarter projected to experience a -10.00% year-over-year decline and the next quarter a -8.00% decline. The current year is estimated to see a -7.00% revenue decrease.
How has QuidelOrtho Corporation performed in recent earnings reports?
QuidelOrtho Corporation recently reported a significant EPS beat for the quarter to June 2026, but this was accompanied by a sharp stock price decline. Previous earnings have shown inconsistency, including a substantial EPS miss in the quarter to March 2026.
What are the main risks facing QuidelOrtho Corporation?
Key risks include persistent negative profitability, a high debt-to-equity ratio of 1.73, and a bearish technical trend indicated by the stock trading below its major moving averages.
What is QDEL stock forecast for 2030?
Based on Monte Carlo simulations, QuidelOrtho Corporation's stock forecast for 2030 shows a base price of $10.56, with a downside projection of $2.93 and an upside projection of $38.03. These are simulation outcomes, not price targets.
What is the Wall Street consensus for QuidelOrtho Corporation?
The Wall Street consensus for QuidelOrtho Corporation is 'Hold', with a score of 42 out of 100, based on ratings from 3 analysts. The median price target is $12.00, suggesting a 9.7% upside from the current price.